These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 24713467)

  • 1. Lessons from SAVOR and EXAMINE: some important answers, but many open questions.
    Schernthaner G; Sattar N
    J Diabetes Complications; 2014; 28(4):430-3. PubMed ID: 24713467
    [No Abstract]   [Full Text] [Related]  

  • 2. Dipeptidyl peptidase-4 inhibitors and cardiovascular safety.
    Davis TM
    Med J Aust; 2014 May; 200(8):450-1. PubMed ID: 24794596
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.
    White WB; Pratley R; Fleck P; Munsaka M; Hisada M; Wilson C; Menon V
    Diabetes Obes Metab; 2013 Jul; 15(7):668-73. PubMed ID: 23489301
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No benefit of saxagliptin on cardiovascular outcomes in type 2 diabetes mellitus: potential explanations.
    Jialal I; Dhindsa S
    Metab Syndr Relat Disord; 2014 Apr; 12(3):157-8. PubMed ID: 24520851
    [No Abstract]   [Full Text] [Related]  

  • 5. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
    Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
    Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An update on the 'gliptins'.
    Drug Ther Bull; 2016 Dec; 54(12):138-141. PubMed ID: 27979881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saxagliptin demonstrates no increased risk for cardiovascular death, heart attack or stroke in the SAVOR cardiovascular outcomes trial.
    Hardy G
    Cardiovasc J Afr; 2013 Aug; 24(7):290. PubMed ID: 24217308
    [No Abstract]   [Full Text] [Related]  

  • 8. Baseline differences in the SAVOR trial.
    Luijendijk HJ; Hulshof TA
    Diabetes Obes Metab; 2015 Dec; 17(12):1202. PubMed ID: 26094750
    [No Abstract]   [Full Text] [Related]  

  • 9. Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?
    Clifton P
    Clin Ther; 2014 Dec; 36(12):2072-2079. PubMed ID: 25453730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New oral hypoglycaemics fail to show cardiovascular benefits.
    Cohen D
    BMJ; 2013 Sep; 347():f5458. PubMed ID: 24014343
    [No Abstract]   [Full Text] [Related]  

  • 11. Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS.
    Schernthaner G; Cahn A; Raz I
    Diabetes Care; 2016 Aug; 39 Suppl 2():S210-8. PubMed ID: 27440835
    [No Abstract]   [Full Text] [Related]  

  • 12. New drugs improve glycemic control in type 2 diabetes, but improving heart health remains elusive.
    Mitka M
    JAMA; 2013 Oct; 310(14):1435-6. PubMed ID: 24104360
    [No Abstract]   [Full Text] [Related]  

  • 13. [Dipeptidylpeptidase-4 (DPP-4) inhibitor sitagliptin. Cardiovascular safety in type 2 diabetics].
    MMW Fortschr Med; 2014 Jul; 156(13):74-5. PubMed ID: 25318234
    [No Abstract]   [Full Text] [Related]  

  • 14. EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.
    White WB; Bakris GL; Bergenstal RM; Cannon CP; Cushman WC; Fleck P; Heller S; Mehta C; Nissen SE; Perez A; Wilson C; Zannad F
    Am Heart J; 2011 Oct; 162(4):620-626.e1. PubMed ID: 21982652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Saxagliptin: a new dipeptidyl peptidase 4 inhibitor for type 2 diabetes.
    Borja-Hart NL; Whalen KL
    Ann Pharmacother; 2010 Jun; 44(6):1046-53. PubMed ID: 20460554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapeutic use and adverse events of incretin-related drugs].
    Ishikawa M; Yamada Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.
    Kaneko M; Narukawa M
    Ann Pharmacother; 2017 Jul; 51(7):570-576. PubMed ID: 28622738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Saxagliptin and tuberculosis.
    Prescrire Int; 2013 Jan; 22(134):17. PubMed ID: 23383408
    [No Abstract]   [Full Text] [Related]  

  • 19. Alogliptin (nesina) for type 2 diabetes.
    Med Lett Drugs Ther; 2013 May; 55(1417):41-3. PubMed ID: 23715128
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.
    Koska J; Sands M; Burciu C; Reaven P
    Diab Vasc Dis Res; 2015 May; 12(3):154-63. PubMed ID: 25852133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.